Tjensvoll, Anne B.
Lauvsnes, Maria B.
Zetterberg, Henrik
Kvaløy, Jan T.
Kvivik, Ingeborg
Maroni, Stian S.
Greve, Ole J.
Beyer, Mona K.
Hirohata, Shunsei
Putterman, Chaim
Alves, Guido
Harboe, Erna
Blennow, Kaj
Gøransson, Lasse G.
Omdal, Roald http://orcid.org/0000-0002-6051-4658
Funding for this research was provided by:
Norsk Revmatikerforbund
Helse Vest Regionalt Helseføretak (911807)
University of Bergen
Article History
Received: 9 July 2020
Revised: 20 October 2020
Accepted: 20 October 2020
First Online: 30 October 2020
Compliance with ethical standards
:
: Dr. Henrik Zetterberg reports that he served on scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Dr. Mona Beyer has received honoraria for lecturing, from Novartis and Biogen Idec, Merck AB, Roche Norge, and Sanofi Genzyme. Dr. Kaj Blennow has served as a consultant or on advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis, and Roche Diagnostics, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Dr. Roald Omdal has received speaker honoraria from several pharmaceutical companies. The other authors report no conflicts of interest.
: This study complied with the Helsinki Declaration and was approved by the Regional Research Ethics Committee (REKvest 2010/1455).
: Written informed consent was obtained from all patients.
: NA.